Antimycotic Prophylaxis in Pediatric Patients Following Allogeneic Stem Cell Transplantation

NCT01040156 · Status: COMPLETED · Type: OBSERVATIONAL

Last updated 2009-12-29

No results posted yet for this study

Summary

Pediatric patients are at high risk to acquire mycotic infections following allogeneic bone marrow transplantation. In the present retrospective analysis we assess the safety and efficacy of different regimens in antimycotic prophylaxis.

Conditions

  • Systemic Aspergillosis
  • Systemic Candidiasis

Sponsors & Collaborators

  • University Children's Hospital Tuebingen

    lead OTHER

Principal Investigators

  • Ingo Mueller, M.D. · UCHT

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01040156 on ClinicalTrials.gov